SCHEMBL4454538

SCHEMBL4454538

CCCCCC(=O)c1cc2ccccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.62
DRD3 P35462 1/20 0.62
IDO1 P14902 3/20 0.57
FLT3 P36888 1/20 0.56
KDM4E B2RXH2 4/20 0.54
HPGD P15428 2/20 0.54
MAPT P10636 1/20 0.54
DAO P14920 1/20 0.54
SRD5A2 P31213 1/20 0.54
HSD17B10 Q99714 1/20 0.54
GAA P10253 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPK1 P28482 1/20 0.53
PDGFRB P09619 3/20 0.51
PDGFRA P16234 3/20 0.51
CCKBR P32239 1/20 0.50
MAOB P27338 1/20 0.50
HDAC1 Q13547 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC3 O15379 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9633071 0.89 IDO1 (0.62) DRD2DRD3IDO1FLT3KDM4E
SCHEMBL30148093 0.82 IDO1 (0.66) DRD2DRD3IDO1FLT3KDM4E
SCHEMBL2730199 0.82 IDO1 (0.66) DRD2DRD3IDO1FLT3KDM4E
SCHEMBL3381105 0.81 HDAC1 (0.73) IDO1FLT3KDM4EGAAALDH1A1
SCHEMBL3380994 0.81 HDAC1 (0.73) IDO1FLT3KDM4EGAAALDH1A1
SCHEMBL9100296 0.81 IDO1 (0.64) DRD2DRD3IDO1FLT3KDM4E
SCHEMBL717286 0.80 F7 (0.56) IDO1FLT3HRH4
SCHEMBL28038704 0.80 IDO1 (0.59) DRD2DRD3IDO1FLT3KDM4E
SCHEMBL29429015 0.79 DRD2 (0.52) DRD2DRD3FLT3KDM4EHPGD
SCHEMBL3380341 0.79 HDAC1 (0.49) DRD2DRD3IDO1FLT3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed
EP-0278265-A1 1- [(4-Morpholinyl) alkyl] -1H-indoles useful as analgesics and preparation thereof STERLING WINTHROP INC. (US) 1988-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL DRD2 4600/4885DRD3 4571/4885IDO1 3078/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL DRD2 4600/4885DRD3 4571/4885IDO1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.